Table 2.

Treatment-related grade ≥3 nonhematologic adverse events after pembrolizumab

ToxicityNumber (total %)
Electrolyte abnormalities
 Hypokalemia1 (3%)
Hepatic
 ALT increase2 (5%)
 AST increase2 (5%)
 Alkaline phosphatase increase2 (5%)
 Lymphocytic infiltration of liver1 (3%)
Infections
 Catheter-related infection3 (8%)
 Clostridium difficile colitis1 (3%)
 Febrile neutropenia23 (62%)
 Hepatic infection1 (3%)
 Lung infection10 (26%)
 Typhlitis1 (3%)
Pulmonary
 Pulmonary edema1 (3%)
Skin
 Maculopapular rash2 (5%)
  • NOTE: The proportion of grade ≥3 nonhematologic adverse events related to pembrolizumab is shown in this table.